Market Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement

MT Newswires Live2024-10-30

Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News reported Tuesday.

This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.

Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479218335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479218335","market":"nz","top_or_hot":-1,"title":"Market Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement","media":"MT Newswires Live","content":"<html><body><p> Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News reported Tuesday.</p><p>This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.</p><p>Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479218335","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479218335","pubTimestamp":1730255321,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Celltrion  secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers , Pulse News reported Tuesday.This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PBM":"Psyence Biomedical Ltd"},"translate_title":"市场热议：赛特瑞恩的Zymfentra通过新的PBM协议获得广泛的美国保险覆盖","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBM":1},"content_text":"Celltrion (KRX:068270) secured a listing for Zymfentra, its subcutaneous autoimmune treatment, on six major US insurance plans under one of the top three pharmacy benefit managers (PBMs), Pulse News reported Tuesday.This inclusion boosts patient access by making Zymfentra, or infliximab-dyyb, eligible for insurance reimbursement across multiple networks, the report said.Approved by the US FDA in October 2023 and launched in March 2024, Zymfentra allows patients to self-administer infliximab at home. With this agreement, Zymfentra is now covered by over 90% of the US insurance market, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479218335"}